NeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene Editing
Portfolio Pulse from Vandana Singh
NeuBase Therapeutics announced positive preclinical safety and efficiency data for its Stealth Editors gene editing program, demonstrating a non-immunogenic system. The company plans to present additional data throughout 2023, including initial non-human primate and mouse data.
May 22, 2023 | 4:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuBase Therapeutics' Stealth Editors gene editing program shows promising preclinical data, leading to a 6.93% increase in stock price.
The positive preclinical data for NeuBase Therapeutics' Stealth Editors gene editing program demonstrates the potential of the technology, which could lead to increased investor interest and demand for the stock. This has resulted in a 6.93% increase in the stock price, indicating a positive short-term impact on the company's shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100